

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	10/586,501
Filing Date	September 14, 2007
First Named Inventor	Martin Hendrix
Art Unit	1624
Examiner Name	Deepak R. Rao
Attorney Docket Number	01-2118

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	A1	3 169 965	05-05-1961	Schmidt et al.	
	A2	3 211 731	10-12-1965	Schmidt et al.	
	A3	7 615 558	11-10-2009	Hendrix	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	B1	WO-2006 125548	11-30-2006	Bayer Healthcare AG		C3
	B2	CH-398 626	03-15-1966	CIBA GEIGY		A2
	B3	GB-937 723	09-25-1963	CIBA LTD		
	B4	WO-2004 096811	11-11-2004	PFIZER PROD INC		
	B5	WO-2004 099210	11-18-2004	BAYER HEALTHCARE AG		A3
	B6	WO-2004 099211	11-18-2004	BAYER HEALTHCARE AG		C4

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	WANG ET AL., "Insight into binding of phosphodiesterase-9-A selective inhibitors by crystal structures and mutagenesis," J. Med. Chem., October 12, 2009	
	C2	DENINNO ET AL., "The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents," Bioorganic & Medicinal Chemistry Letters, 2009, Vol. 9, pp. 2537-2541	
	C3	HENDRIX ET AL., "Use of Pyrazolopyrimidine Against Cardiovascular Disease," Publication Date: November 30, 2006, Data Supplied from the espacenet database Worldwide; English Abstract of WO 2006125548	
	C4	HENDRIX ET AL., "6-cyclymethyl- and 6-alkylmethyl-Substituted Pyrazolopyrimidines," Publication Date: November 18, 2004, Data Supplied from the espacenet database Worldwide; English Abstract of WO 2004099211	
	C5	WUNDER ET AL., "Characterization of the first potent and selective PDE9 inhibitor using a cGMP Reporter Cell Line," Molecular Pharmacology, 2005, Vol. 68, pp. 1775-1781	

Examiner  
Signature

/Deepak Rao/

Date  
Considered

10/14/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**